Top Page
PYC Therapeutics Limited
(Sydney:PYC)
PYC Therapeutics Limited (PYC) vs. iShares MSCI Australia ETF (EWA)
PYC Therapeutics Limited Business Overview & Revenue Model
PYC Therapeutics Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.49M | 23.49M | 22.06M | 15.81M | 16.04M | 3.07M |
| Gross Profit | 23.49M | 23.49M | 22.06M | 14.92M | 15.20M | 2.45M |
| EBITDA | -52.88M | -52.88M | -54.55M | -38.25M | -29.39M | -21.04M |
| Net Income | -50.30M | -50.30M | -37.73M | -22.79M | -13.86M | -17.77M |
Balance Sheet | ||||||
| Total Assets | 183.28M | 183.28M | 91.24M | 37.17M | 45.35M | 57.94M |
| Cash, Cash Equivalents and Short-Term Investments | 153.05M | 153.05M | 66.87M | 15.57M | 29.11M | 51.50M |
| Total Debt | 1.02M | 1.02M | 1.11M | 315.49K | 943.77K | 730.35K |
| Total Liabilities | 13.27M | 13.27M | 10.18M | 8.72M | 5.15M | 4.02M |
| Stockholders Equity | 169.57M | 169.57M | 80.50M | 27.75M | 39.35M | 53.04M |
Cash Flow | ||||||
| Free Cash Flow | -52.54M | -52.54M | -38.90M | -24.91M | -22.17M | -12.38M |
| Operating Cash Flow | -51.56M | -51.56M | -38.59M | -24.42M | -21.78M | -11.79M |
| Investing Cash Flow | -975.40K | -975.40K | -307.04K | -477.12K | 32.68M | -15.52M |
| Financing Cash Flow | 138.66M | 138.66M | 90.19M | 11.44M | -182.36K | 38.56M |
PYC Therapeutics Limited Technical Analysis
PYC Therapeutics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$631.53M | 17.41 | 15.90% | 0.39% | 7.76% | 1.55% | |
53 Neutral | AU$1.09B | -16.02 | -54.37% | ― | ― | -29.93% | |
53 Neutral | AU$226.63M | -2.46 | -90.93% | ― | 456.50% | -457.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$869.06M | -14.47 | -40.23% | ― | ― | -5.70% | |
49 Neutral | AU$545.28M | -9.24 | -35.86% | ― | ― | -19.21% | |
30 Underperform | AU$738.77M | -2.95 | ― | ― | -80.08% | 59.91% |
PYC Therapeutics Limited Corporate Events
PYC Therapeutics Limited announced a change in the director’s interest as Dr. Rohan Hockings acquired 133,350 ordinary shares through an on-market purchase valued at $200,003. This acquisition reflects a significant personal investment by the director, potentially indicating confidence in the company’s future prospects and strategic direction.
PYC Therapeutics Limited has received approval from the Safety Review Committee to escalate dosing in the clinical trial of its drug candidate PYC-003 for Polycystic Kidney Disease. This approval marks a significant step in the Single Ascending Dose study, allowing the company to proceed to the second cohort, and is part of a broader strategy to advance towards a registrational trial aimed at supporting a New Drug Application.
PYC Therapeutics Limited announced changes in its board of directors, with Peter Coleman being appointed as a new director and Alan Tribe concluding his directorship. These changes may impact the company’s strategic direction and governance, potentially influencing its operations and stakeholder interests.
PYC Therapeutics Limited announced the results of its Annual General Meeting, where Resolutions 1 and 3 were passed, while Resolution 2 was withdrawn. The approval of these resolutions reflects the company’s ongoing governance and strategic direction, potentially impacting its operations and industry positioning.
PYC Therapeutics Limited has provided an update on its business operations, emphasizing its drug development pipeline. The company’s investigational drug candidates are still under development and have not received regulatory approval, highlighting the ongoing risks and uncertainties in its operations.
PYC Therapeutics Limited has announced promising results from its ongoing Phase 1/2 clinical trials of VP-001, an investigational drug candidate for Retinitis Pigmentosa type 11 (RP11). Patients treated with VP-001 have shown sustained improvements in vision and retinal sensitivity up to 18 months post-treatment, with the treated eyes outperforming untreated eyes and a natural history control group across all measured endpoints. The drug has demonstrated a favorable safety profile with no serious adverse events reported, and PYC is preparing to engage with the US FDA to design a registrational trial expected to commence in 2026.
PYC Therapeutics Limited has announced the appointment of Peter Coleman as the new Independent Non-Executive Chair, effective after the 2025 Annual General Meeting. This leadership change is part of a broader board renewal process, with current Chair Alan Tribe stepping down. Coleman, with a background in corporate governance and mergers, is expected to guide PYC through its next growth phase, potentially opening new commercial avenues. The company is also undergoing changes in its executive team, with Andrew Taylor resigning as co-Company Secretary and CFO, while Kevin Hart will continue as the sole Company Secretary. These strategic shifts aim to align with long-term shareholder value creation and strengthen PYC’s position in the RNA therapy market.
PYC Therapeutics Limited has announced that its Annual General Meeting will be held on November 18, 2025, at the Harry Perkins Institute of Medical Research in Western Australia. The meeting will be accessible both in-person and via Zoom, allowing shareholders to participate remotely, which reflects the company’s commitment to engaging with its stakeholders and maintaining transparency in its operations.
PYC Therapeutics Limited announced significant progress in its drug development programs during Q3 2025, advancing all four of its precision medicine candidates. Key developments include moving into new study phases for treatments targeting Polycystic Kidney Disease, Retinitis Pigmentosa type 11, Autosomal Dominant Optic Atrophy, and Phelan-McDermid Syndrome. These advancements are crucial for the company as it prepares for upcoming human safety and efficacy read-outs, which could impact its market positioning and offer new hope for patients with unmet medical needs.
PYC Therapeutics Limited has initiated a global Phase 1b clinical trial, known as the MYRTLE study, for its investigational drug PYC-001, aimed at treating Autosomal Dominant Optic Atrophy (ADOA). The study will assess the safety, tolerability, and efficacy of repeat dosing of PYC-001, with initial dosing already administered to the first patient. This trial marks a significant step in establishing clinical proof of concept for PYC-001, potentially leading to a registrational study and offering hope for patients with no current treatment options.
PYC Therapeutics Limited has announced its Annual General Meeting will be held on November 18, 2025, at the Harry Perkins Institute of Medical Research in Western Australia. This meeting is significant for stakeholders as it provides insights into the company’s strategic direction and operational updates, reinforcing its commitment to advancing RNA therapies in the biotechnology sector.
PYC Therapeutics Limited has released a presentation providing an update on its business operations. The presentation emphasizes the company’s ongoing commitment to advancing its therapeutic solutions, although it advises stakeholders to consider the inherent risks and uncertainties associated with forward-looking statements.
PYC Therapeutics Limited announced an upcoming investor webinar scheduled for October 13, 2025, to discuss recent changes in its board and management team, as well as progress in its four drug development programs. This event reflects the company’s ongoing commitment to transparency and engagement with stakeholders, highlighting its strategic focus on advancing its RNA therapeutic pipeline and strengthening its industry position.
PYC Therapeutics Limited has announced changes in its board of directors, with new appointments and final interest notices for several directors. These changes are part of the company’s ongoing efforts to strengthen its leadership team as it continues to advance its RNA therapeutic programs, which could impact its market positioning and stakeholder interests.
PYC Therapeutics has announced significant changes to its Board and Executive management team to support its growth ambitions. Dr. Rohan Hockings has been re-appointed as Managing Director, and Prof. Ian Constable joins as a Non-Executive Director, bringing extensive experience in drug development. These changes are part of PYC’s strategy to advance its pipeline of drug candidates into late-stage clinical development, preparing for substantial growth and multiple concurrent clinical programs.
PYC Therapeutics Limited has issued a correction to a previous trading halt request, clarifying that the halt is related to pending changes in the company’s board and management, not a capital raising as initially stated. This announcement underscores the company’s focus on restructuring its leadership, which may impact its strategic direction and operations, potentially influencing stakeholder confidence and market positioning.
PYC Therapeutics Limited has requested a trading halt on its securities pending an important announcement concerning changes to its board and management. This move is part of a broader strategy that includes a proposed capital raising, which could have significant implications for the company’s future operations and market positioning.